Bexarotene - a novel modulator of AURKA and the primary cilium in VHL -deficient cells

Loss of the gene von Hippel-Lindau ( ) is associated with loss of primary cilia and is causally linked to elevated levels of Aurora kinase A (AURKA). We developed an image-based high-throughput screening (HTS) assay using a dual-labeling image analysis strategy that identifies both the cilium and th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cell science 2018-12, Vol.131 (24)
Hauptverfasser: Chowdhury, Pratim, Powell, Reid T, Stephan, Clifford, Uray, Ivan P, Talley, Tia, Karki, Menuka, Tripathi, Durga Nand, Park, Yong Sung, Mancini, Michael A, Davies, Peter, Dere, Ruhee
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Loss of the gene von Hippel-Lindau ( ) is associated with loss of primary cilia and is causally linked to elevated levels of Aurora kinase A (AURKA). We developed an image-based high-throughput screening (HTS) assay using a dual-labeling image analysis strategy that identifies both the cilium and the basal body. By using this strategy, we screened small-molecule compounds for the targeted rescue of cilia defects associated with deficiency with high accuracy and reproducibility. Bexarotene was identified and validated as a positive regulator of the primary cilium. Importantly, the inability of an alternative retinoid X receptor (RXR) agonist to rescue ciliogenesis, in contrast to bexarotene, suggested that multiple bexarotene-driven mechanisms were responsible for the rescue. We found that bexarotene decreased AURKA expression in -deficient cells, thereby restoring the ability of these cells to ciliate in the absence of Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with deficiency and elevated AURKA expression.
ISSN:0021-9533
1477-9137
DOI:10.1242/jcs.219923